» Articles » PMID: 37843220

Genetic and Epigenetic Targets of Natural Dietary Compounds As Anti-Alzheimer's Agents

Overview
Date 2023 Oct 16
PMID 37843220
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease is a progressive neurodegenerative disorder and the most common cause of dementia that principally affects older adults. Pathogenic factors, such as oxidative stress, an increase in acetylcholinesterase activity, mitochondrial dysfunction, genotoxicity, and neuroinflammation are present in this syndrome, which leads to neurodegeneration. Neurodegenerative pathologies such as Alzheimer's disease are considered late-onset diseases caused by the complex combination of genetic, epigenetic, and environmental factors. There are two main types of Alzheimer's disease, known as familial Alzheimer's disease (onset < 65 years) and late-onset or sporadic Alzheimer's disease (onset ≥ 65 years). Patients with familial Alzheimer's disease inherit the disease due to rare mutations on the amyloid precursor protein (APP), presenilin 1 and 2 (PSEN1 and PSEN2) genes in an autosomal-dominantly fashion with closely 100% penetrance. In contrast, a different picture seems to emerge for sporadic Alzheimer's disease, which exhibits numerous non-Mendelian anomalies suggesting an epigenetic component in its etiology. Importantly, the fundamental pathophysiological mechanisms driving Alzheimer's disease are interfaced with epigenetic dysregulation. However, the dynamic nature of epigenetics seems to open up new avenues and hope in regenerative neurogenesis to improve brain repair in Alzheimer's disease or following injury or stroke in humans. In recent years, there has been an increase in interest in using natural products for the treatment of neurodegenerative illnesses such as Alzheimer's disease. Through epigenetic mechanisms, such as DNA methylation, non-coding RNAs, histone modification, and chromatin conformation regulation, natural compounds appear to exert neuroprotective effects. While we do not purport to cover every in this work, we do attempt to illustrate how various phytochemical compounds regulate the epigenetic effects of a few Alzheimer's disease-related genes.

Citing Articles

Targeting natural antioxidant polyphenols to protect neuroinflammation and neurodegenerative diseases: a comprehensive review.

Jalouli M, Rahman M, Biswas P, Rahman H, Harrath A, Lee I Front Pharmacol. 2025; 16:1492517.

PMID: 39981183 PMC: 11840759. DOI: 10.3389/fphar.2025.1492517.


Alzheimer's Disease: Exploring Pathophysiological Hypotheses and the Role of Machine Learning in Drug Discovery.

Dominguez-Gortaire J, Ruiz A, Porto-Pazos A, Rodriguez-Yanez S, Cedron F Int J Mol Sci. 2025; 26(3).

PMID: 39940772 PMC: 11816687. DOI: 10.3390/ijms26031004.


The Activation of Muscarinic Acetylcholine Receptors Protects against Neuroinflammation in a Mouse Model through Attenuating Microglial Inflammation.

Wang K, Xie Y, Chen X, Ouyang X, Zhao L, Chen H Int J Mol Sci. 2024; 25(19).

PMID: 39408758 PMC: 11476571. DOI: 10.3390/ijms251910432.


Progress of research in the application of ultrasound technology for the treatment of Alzheimer's disease.

Cai Q, Meng L, Quan M, Wang L, Ren J, Zheng C Neural Regen Res. 2024; 20(10):2823-2837.

PMID: 39314155 PMC: 11826464. DOI: 10.4103/NRR.NRR-D-24-00539.


Investigating the Neuroprotective and Cognitive-Enhancing Effects of : A Systematic Review Focused on Inflammation, Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis.

Valotto Neto L, Reverete de Araujo M, Moretti Junior R, Machado N, Joshi R, Dos Santos Buglio D Antioxidants (Basel). 2024; 13(4).

PMID: 38671841 PMC: 11047749. DOI: 10.3390/antiox13040393.


References
1.
Mukerjee N, Das A, Jawarkar R, Maitra S, Das P, Castrosanto M . Repurposing food molecules as a potential BACE1 inhibitor for Alzheimer's disease. Front Aging Neurosci. 2022; 14:878276. PMC: 9443073. DOI: 10.3389/fnagi.2022.878276. View

2.
Hyun K, Jeon J, Park K, Kim J . Writing, erasing and reading histone lysine methylations. Exp Mol Med. 2017; 49(4):e324. PMC: 6130214. DOI: 10.1038/emm.2017.11. View

3.
Zhou B, Lu J, Siddu A, Wernig M, Sudhof T . Synaptogenic effect of -Swedish mutation in familial Alzheimer's disease. Sci Transl Med. 2022; 14(667):eabn9380. PMC: 9894682. DOI: 10.1126/scitranslmed.abn9380. View

4.
Rovio S, Kareholt I, Helkala E, Viitanen M, Winblad B, Tuomilehto J . Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol. 2005; 4(11):705-11. DOI: 10.1016/S1474-4422(05)70198-8. View

5.
Dileep V, Tsai L . Three-dimensional chromatin organization in brain function and dysfunction. Curr Opin Neurobiol. 2021; 69:214-221. DOI: 10.1016/j.conb.2021.04.006. View